Prof. Birkenfeld in Sächsische Zeitung

Prof. Birkenfeld in Sächsische Zeitung with the topic “How your lifestyle advances diabetes”.

(Article in German)

Eternygen at BioFIT 2017

Eternygen was invited to join panel discussion at BioFIT 2017 conference “How are collaborations key to improve innovation in metabolic diseases?” in Strasbourg (28 – 29 November 2017)

(BioFIT programme)

Eternygen GmbH is part of the Network for Pharma Solutions (NetPhaSol, Germany)

Eternygen GmbH is part of the Network for Pharma Solutions (NetPhaSol, Germany)

Press release

Eternygen GmbH closes € 8.0 (US$ 8.3) million Series A financing

Eternygen GmbH Closes € 8.0 (US$ 8.3) million Series A financing led by Epidarex Capital

Press release

Prof. Jordan takes on position as Head of the Institute of Aerospace Medicine

Prof. Jordan takes on position as Head of the Institute of Aerospace Medicine starting on 1st of December 2016 at the German Aerospace Center in Cologne

Eteryngen at 7th International IQPC Conference

Eternygen GmbH today announced that its head of research will present at the 7th International IQPC Conference “Clinically Relevant Drug Transporter”, June 21-23, 2016 to be held at the Hotel Palace in Berlin Germany.

Download press release 

BioEquity Europe Conference

Eternygen GmbH will present a corporate overview of the company at the 16 th BioEquity Europe Conference, May 19-20, 2015 “Next Wave Companies” to be held at the Hotel InterContinental in Vienna, Austria. Presentation held by Dr. Grit Zahn.

download press statement
further information

Evotec and Eternygen Cooperation

Evotec and Eternygen enter collaboration to identify and develop novel metabolic disease therapy.

download press statement

Dr. Grit Zahn new head of research

Eternygen appoints Dr. Grit Zahn as Head of Research.

download press statement

Eternygen GmbH receives funding

Eternygen GmbH receives funding from IBB Beteiligungsgesellschaft.

download press statement